Premium
Enhancement of tumor‐liver contrast‐to‐noise ratio with gadobenate dimeglumine in MR imaging of rats
Author(s) -
Kreft Burkhard P.,
Tanimoto Akihiro,
Stark David D.,
Baba Yuji,
Zhao Longhai,
Chen John T.,
Compton Carolyn C.,
Paul Finn J.,
Cavagna Friedrich M.
Publication year - 1993
Publication title -
journal of magnetic resonance imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.563
H-Index - 160
eISSN - 1522-2586
pISSN - 1053-1807
DOI - 10.1002/jmri.1880030109
Subject(s) - medicine , magnetic resonance imaging , parenchyma , vascularity , liver tumor , in vivo , gadolinium , liver parenchyma , contrast enhancement , hepatocellular carcinoma , nuclear medicine , pathology , radiology , chemistry , microbiology and biotechnology , organic chemistry , biology
The efficacy for tumor detection of the hepatocyte‐specific contrast agent gadobenate dimeglumine (gadolinium‐BOPTA/Dimeg) was evaluated in four different experimental tumor models in rats. Histo‐logic findings were correlated with quantitative data derived from ex vivo relaxometry and in vivo magnetic resonance (MR) imaging. Noninfiltrating tumors showed maximal enhancement of liver parenchyma 5–10 minutes after contrast agent administration, with a plateau over the next 30 minutes. In contrast, infiltrating tumors, which caused hepatocellular injury and inflammatory changes, delayed maximal enhancement of tumor‐free parenchyma by 15–20 minutes. Nonspecific tumor enhancement depended on tumor vascularity and occurred in the early phase after contrast agent administration. Despite differences in specific enhancement of tumor‐free parenchyma and nonspecific tumor enhancement, tumor‐liver contrast‐to‐noise ratios increased 96%–248% in all tumor models 30 minutes after intravenous administration of 75 mmol/kg Gd‐BOPTA/Dimeg. Gd‐BOPTA/Dimeg enhanced tumor conspicuity independently of the histologic characteristics of the tumor.